Australia's most trusted
source of pharma news
Tuesday, 01 July 2025
Posted 30 June 2025 AM
Two new drugs – Biogen’s Skyclarys and Amgen’s Imdelltra – plus the first biosimilar of a tyrosine kinase inhibitor were among products registered on the ARTG last week.
Skyclarys is the first and only treatment for Friedrich’s ataxia, a rare genetic neuromuscular disorder with a life expectancy of 37 years on average. It has been approved for adults and adolescents aged 16 years and older.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.